Radium Ra 223 Dichloride Articles

Articles

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer - Abstract
Background: Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases.
Published July 19, 2013
FDA approves new drug for advanced prostate cancer

BERKELEY, CA USA (Press Release) - May 15, 2013 -

Xofigo approved three months ahead of schedule under priority review program

Published May 15, 2013
The New England Journal of Medicine publishes results from the phase III ALSYMPCA study of Xofigo® (radium Ra 223 dichloride) injection

WHIPPANY, NJ USA (Press Release) - July 17, 2013 - Bayer HealthCare today announced that data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomaticProstate CAncer) trial of its drug Xofigo® (radium Ra 223 dichloride) in castration-resistant prostate cancer (CRPC) patients with symptomatic bone metastases and no known visceral metastatic disease are published in the July 18 issue of the New England Journal of Medicine (NEJM).
Published July 19, 2013